270 Developing placental CD34+-derived natural killer cells with high affinity and cleavage resistant CD16 (CYNK-101) in combination with avelumab for enhanced therapy against PD-L1+solid tumors
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.